Literature DB >> 2317560

Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia.

L Trentin1, R Zambello, C Agostini, A Ambrosetti, T Chisesi, R Raimondi, P Bulian, G Pizzolo, G Semenzato.   

Abstract

Natural killer (NK) cell activity is severely impaired in untreated patients with hairy cell leukemia (HCL). In an attempt to investigate whether this impairment is related to a defect at the target cell binding and/or at the post target cell binding level, we evaluated the peripheral blood mononuclear cells (PBMC) of HCL patients for their ability to: (1) bind and kill K-562 NK-sensitive targets at the single cell binding level; (2) release the NK cytotoxic factor (NKCF) under different in vitro stimuli, including K-562 and phytohemoagglutinin; and (3) kill K-562 targets in a lectin-dependent cellular cytoxicity (LDCC) assay. This study demonstrates that untreated HCL patients' PBMC show a low ability to form conjugates with K-562 targets at the single cell binding level (5.7% +/- 1.0%) with respect to patients studied after treatment (9.3% +/- 1.3%) and controls (15.0% +/- 4.0%); P less than .05 and P less than .001, respectively. A decreased ability to kill the bound target was demonstrated in untreated cases (1.2% +/- 1.1%) versus patients studied after treatment and controls (12.3% +/- 1.6%, 17.0% +/- 3.1% respectively); P less than .001 in both conditions. After activation of effector cells with interleukin-2 (IL-2) in vitro, an increase in the ability of PBMC to form conjugates with K-562 targets and kill the bound target was demonstrated in each group of patients. Moreover, IL-2 was able to increase the cytotoxicity against NK-sensitive targets in all patients tested. Evaluation of NKCF production showed that untreated patients release low levels of NKCF when PBMC were incubated in the presence of K-562 stimulators (1.8% +/- 0.7%) with respect to patients after interferon-alpha (IFN-alpha) therapy (7.6% +/- 2.1%) and controls (12.9% +/- 2.2%); P less than .02 and P less than .001, respectively. When the recognition mechanisms were bypassed by triggering the cells with lectins in an LDCC assay, we demonstrated an increase of the lytic activity in both groups of patients with respect to the baseline values. However, the cytotoxic capacity observed in untreated patients was significantly lower than that observed in subjects after IFN-alpha therapy and controls (P less than .001). These findings suggest that the impaired NK activity observed in patients with HCL is related to defects both at the target and posttarget cell binding levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317560

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis.

Authors:  L Trentin; C Agostini; M Facco; F Piazza; A Perin; M Siviero; C Gurrieri; S Galvan; F Adami; R Zambello; G Semenzato
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

2.  Histoplasmosis in hairy cell leukemia: case report and review of the literature.

Authors:  E Weeks; C M Jones; V Guinee; R Shallenberger; G A Sarosi; P A Bunnell
Journal:  Ann Hematol       Date:  1992-09       Impact factor: 3.673

3.  Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients.

Authors:  A M Liberati; V De Angelis; M Fizzotti; M Schippa; M Cecchini; D Adiuto; F Di Clemente; L Palmisano; E Micozzi; M Zuccaccia
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

4.  Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; C Enthammer; M Cassatella; D Nitti; M Lise; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

5.  Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers.

Authors:  Rachel M Koldej; Ashvind Prabahran; Chin Wee Tan; Ashley P Ng; Melissa J Davis; David S Ritchie
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.